期刊
BIOMOLECULES
卷 11, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/biom11030433
关键词
Parkinson's disease; gut microbiota; therapeutic modulation; gut-brain axis; prebiotics; probiotics; antibiotics; synbiotics; Mediterranean diet; fecal transplants; live biotherapeutic products
资金
- La Caixa Banking Foundation [LCF/BQ/PR19/11700005]
Research indicates that gut microbiota plays a crucial role in the development and progression of Parkinson's disease, making microbiota-based therapeutic strategies a potential treatment option. Various microbiota-based treatment strategies have been developed for Parkinson's disease, but the field faces challenges in implementation and further research.
Parkinson's disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor symptoms in patients. Recent interest in the gut-brain axis has led to increasing research into the gut microbiota changes in PD patients and their impact on disease pathophysiology. As evidence is piling up on the effects of gut microbiota in disease development and progression, another front of action has opened up in relation to the potential usage of microbiota-based therapeutic strategies in treating gastrointestinal alterations and possibly also motor symptoms in PD. This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据